Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$10.54 USD
-0.30 (-2.77%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $10.56 +0.02 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Roivant Sciences Ltd. (ROIV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.18 | $23.00 | $12.00 | 49.26% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Roivant Sciences Ltd. comes to $16.18. The forecasts range from a low of $12.00 to a high of $23.00. The average price target represents an increase of 49.26% from the last closing price of $10.84.
Analyst Price Targets (11)
Broker Rating
Roivant Sciences Ltd. currently has an average brokerage recommendation (ABR) of 1.15 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.15 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, 12 are Strong Buy, representing 92.31% of all recommendations. A month ago, Strong Buy represented 92.31%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 11 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.15 | 1.15 | 1.15 | 1.17 | 1.18 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/25/2024 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
2/14/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
2/14/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
1/12/2024 | Cantor Fitzgerald & Co | Louise Chen | Not Available | Strong Buy |
1/5/2024 | Piper Sandler | Allison M Bratzel | Not Available | Strong Buy |
11/15/2023 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.15 |
ABR (Last week) | 1.15 |
# of Recs in ABR | 13 |
Average Target Price | $16.18 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 252 |
Current Quarter EPS Est: | -0.25 |